These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17347661)

  • 1. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men.
    Zitzmann M
    Nat Clin Pract Urol; 2007 Mar; 4(3):161-6. PubMed ID: 17347661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of testosterone replacement therapy.
    Zitzmann M
    Pharmacogenomics; 2009 Aug; 10(8):1341-9. PubMed ID: 19663677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism.
    Zitzmann M
    Asian J Androl; 2008 May; 10(3):364-72. PubMed ID: 18385898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the CAG repeat androgen receptor polymorphism in andrology.
    Zitzmann M
    Front Horm Res; 2009; 37():52-61. PubMed ID: 19011288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study.
    Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
    J Clin Endocrinol Metab; 2003 May; 88(5):2049-54. PubMed ID: 12727953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism?
    Francomano D; Greco EA; Lenzi A; Aversa A
    J Sex Med; 2013 Oct; 10(10):2373-81. PubMed ID: 23844628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor gene CAG repeat polymorphism independently influences recovery of male sexual function after testosterone replacement therapy in postsurgical hypogonadotropic hypogonadism.
    Tirabassi G; Delli Muti N; Corona G; Maggi M; Balercia G
    J Sex Med; 2014 May; 11(5):1302-8. PubMed ID: 24593124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men.
    Zitzmann M; Gromoll J; von Eckardstein A; Nieschlag E
    Diabetologia; 2003 Jan; 46(1):31-9. PubMed ID: 12637980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership.
    Schneider G; Nienhaus K; Gromoll J; Heuft G; Nieschlag E; Zitzmann M
    Psychoneuroendocrinology; 2010 May; 35(4):578-87. PubMed ID: 19804943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAG repeat length analysis and mutation screening of the androgen receptor gene in Japanese men with idiopathic azoospermia.
    Sasagawa I; Suzuki Y; Ashida J; Nakada T; Muroya K; Ogata T
    J Androl; 2001; 22(5):804-8. PubMed ID: 11545293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis.
    Ishii T; Sasaki G; Hasegawa T; Sato S; Matsuo N; Ogata T
    J Urol; 2004 Jul; 172(1):319-24. PubMed ID: 15201804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism.
    Crabbe P; Bogaert V; De Bacquer D; Goemaere S; Zmierczak H; Kaufman JM
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3604-10. PubMed ID: 17579205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Length of androgen receptor-CAG repeats in fertile and infertile Egyptian men.
    Badran WA; Fahmy I; Abdel-Megid WM; Elder K; Mansour R; Kent-First M
    J Androl; 2009; 30(4):416-25. PubMed ID: 19168451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacogenetic approach to improve low ovarian response: The role of CAG repeats length in the androgen receptor gene.
    Lledo B; Llácer J; Ortiz JA; Martinez B; Morales R; Bernabeu R
    Eur J Obstet Gynecol Reprod Biol; 2018 Aug; 227():41-45. PubMed ID: 29886316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone.
    Ghanim H; Dhindsa S; Abuaysheh S; Batra M; Kuhadiya ND; Makdissi A; Chaudhuri A; Dandona P
    Eur J Endocrinol; 2018 Mar; 178(3):277-283. PubMed ID: 29339527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central body fat changes in men affected by post-surgical hypogonadotropic hypogonadism undergoing testosterone replacement therapy are modulated by androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Buldreghini E; Lenzi A; Balercia G
    Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):908-13. PubMed ID: 24787905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism.
    Tirabassi G; Corona G; Biagioli A; Buldreghini E; delli Muti N; Maggi M; Balercia G
    J Sex Med; 2015 Feb; 12(2):381-8. PubMed ID: 25443437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor gene CAG repeat polymorphism in women with polycystic ovary syndrome.
    Kim JJ; Choung SH; Choi YM; Yoon SH; Kim SH; Moon SY
    Fertil Steril; 2008 Dec; 90(6):2318-23. PubMed ID: 18191848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.
    Klotz L; Correia A; Zhang W
    Prostate Cancer Prostatic Dis; 2005; 8(2):179-83. PubMed ID: 15809670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.